share_log

国药现代(600420.SH):硫辛酸注射液获得药品补充申请批准通知书

Shanghai Shyndec Pharmaceutical (600420.SH): Thioctic Acid Injection Approved for Drug Supplementary Application Notification

Gelonghui Finance ·  Jul 18 05:10

On July 18th, Gelunhui reported that Shanghai Shyndec Pharmaceutical's subsidiary, Shanghai XianDai Hassan (Shangqiu) Pharmaceutical Co., Ltd, received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration, approving the increase of 24ml:0.6g specification of thioctic acid injection and passing the consistency evaluation of generic drug quality and efficacy. Thioctic acid injection is used to treat the sensory abnormalities caused by diabetic peripheral neuropathy. According to the Minet database, the national sales of thioctic acid injections in public hospitals in 2023 was RMB 0.521 billion.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment